IL18 and acute myeloid leukemia: In pre-clinical and clinical studies, the Fehniger group has shown that treatment with a cytokine cocktail consisting of IL-12, IL-15 and IL-18 results in development of CIML NK cells with enhanced interferon-γ (IFN-γ) production and cytotoxicity against leukemia cell lines or primary human AML blasts (46–48).